Last updated: April 24, 2026
What did Vanda Pharmaceuticals win (and lose) in Vanda v. Teva (1:18-cv-00651-CFC), and what does the case signal for future exclusivity and generic entry?
Case posture
- Court / case: U.S. District Court for the District of Delaware
- Docket: 1:18-cv-00651-CFC
- Caption: Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.
- Parties (as pleaded): Vanda Pharmaceuticals Inc. (plaintiff) vs. Teva Pharmaceuticals USA, Inc. (defendant)
Is this a Hatch-Waxman patent case tied to a marketed Vanda product?
No usable record-level content is available in the provided inputs to determine:
- which Vanda product or active ingredient was at issue,
- whether the action was brought under 35 U.S.C. § 271(e)(2) as an ANDA infringement suit,
- which specific asserted patents were listed in the infringement complaint,
- whether Teva’s filing triggered a Paragraph IV notice under 21 U.S.C. § 355(j),
- whether the case involved dismissal, summary judgment, trial verdict, a consent judgment, or a stipulated stay.
Because the prompt includes only the case identifier and no docket text, court order excerpts, settlement documents, or patent list, producing an accurate litigation summary is not possible under the operating constraints.
What patents were asserted, and what claims/validity issues were litigated?
Not determinable from the information provided.
A complete and accurate litigation analysis requires, at minimum, the asserted patent numbers (and publication/patent family context), the specific claim terms each side disputed, and the procedural outcomes (e.g., claim construction rulings, validity findings, infringement findings, and any appeal or post-judgment motions). None of that is present in the input.
What was the final outcome in the federal case?
Not determinable from the information provided.
A litigation summary that is “hard data” requires the actual dispositive rulings (e.g., grant/denial of summary judgment, trial judgment, JMOL, final judgment entry, or dismissal with prejudice) and any effective dates tied to generic entry or licensing. None of that is available here.
Key analytic dimensions typically assessed in Vanda vs. generic defendants
These dimensions cannot be populated without docket/order content:
- Claim construction (especially method-of-treatment or dosing regimen language, if present)
- Infringement (ANDA label carve-outs, bioavailability, dosing schedules, and “intended use” arguments)
- Validity (anticipation, obviousness, written description/enablement, and indefiniteness)
- Statutory defenses and procedural constraints (e.g., venue, standing, limitation/estoppel)
- Remedy (injunctive relief or damages)
- Timeline effects (automatic stay duration, any stipulated carve-outs, and generic launch dates)
Business and investment relevance
Even without case specifics, the business relevance of a Hatch-Waxman infringement case depends on concrete inputs: which patents, which claims, the likelihood of success on infringement vs. validity, and whether the court’s result narrows future exclusivity or delays. The provided inputs do not support a credible, numbered factual analysis.
What can be concluded from the docket identifier alone?
Only this:
- The litigation exists in the federal system under the cited docket number.
- No reliable statement can be made about outcome, asserted patents, or legal reasoning.
Key Takeaways
- The provided information does not contain enough record-level detail to produce a complete, accurate litigation summary or patent-focused analysis for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (1:18-cv-00651-CFC).
- No determinate conclusions can be drawn on: asserted patents, claim construction, infringement or validity findings, dispositive outcomes, or exclusivity implications.
FAQs
-
Is this case about an ANDA and a specific Vanda product?
The inputs provided do not identify the product, ANDA, or the asserted patent list.
-
Which Vanda patents were asserted against Teva?
The inputs provided do not include asserted patent numbers.
-
What was the court’s final decision?
The inputs provided do not include the final judgment or dispositive orders.
-
Did the ruling affect Teva’s ability to launch a generic?
The inputs provided do not include any injunction, settlement terms, or effective entry dates.
-
What precedent did the case create for future exclusivity litigation?
The inputs provided do not include the legal holdings needed to assess precedential impact.
References
[1] U.S. District Court for the District of Delaware. Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., No. 1:18-cv-00651-CFC.
